+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07087860

Phase II Study of Therapeutic Plasma Exchange Combined With Enfortumab Vedotin and Pembrolizumab Versus Standard Therapy for Advanced Bladder and Urinary Tract Cancers

Led by Mayo Clinic · Updated on 2026-05-08

70

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating therapeutic plasma exchange TPE combined with enfortumab vedotin and pembrolizumab compared to standard next-line therapies for patients with metastatic bladder or upper urinary tract cancers that have not responded to previous treatments. This phase II trial also assesses TPE with standard antibody drug conjugates ADCs in treating refractory metastatic bladder cancer. The study aims to compare response rates, survival outcomes, safety, and quality of life between these treatments. Participants are assigned to one of three groups. Group A receives TPE on days 1-3 of cycles 1-3, enfortumab vedotin intravenously on days 3 and 10 of cycles 1-3 and days 1 and 8 thereafter, and pembrolizumab on day 3 of cycles 1-3 and day 1 thereafter. Group B receives physicians choice of standard next-line therapy. Cohort C receives TPE on days 1-3 of cycles 1-3 and standard ADC therapy intravenously on day 3 of cycles 1-3 and day 1 thereafter. Treatment cycles repeat every 21 days unless disease progresses or toxicity occurs. Participants undergo imaging scans such as CT, PETCT, or MRI and provide blood and urine samples throughout the study. Quality of life is assessed at baseline and every 12 weeks. After treatment completion, patients are followed every 6 months for up to 5 years. The study monitors overall response rate, duration of response, progression-free survival, overall survival, safety, and quality of life to evaluate the impact of these therapies.

CONDITIONS

Brief Title

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Research Team

C

Clinical Trials Referral Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here